10th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160067202 | USE OF A COMPOSITION COMPRISING FISH OIL AND JUICE FOR THE TREATMENT AND/OR POST TREATMENT OF CANCER - Disclosed is a composition including a fish oil and a juice in an oil-in-water emulsion for use in treatment and post-treatment of cancer. | 2016-03-10 |
20160067203 | INTERNAL COMPOSITION - An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients. | 2016-03-10 |
20160067204 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND/OR CONJUNCTIVAL EPITHELIUM DISORDERS - The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered. | 2016-03-10 |
20160067205 | Combination Therapies with Anti-CD38 Antibodies - The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid. | 2016-03-10 |
20160067206 | COMPOSITION FOR PREVENTING OR TREATING RENAL FIBROSIS COMPRISING DIMETHYLFUMARATE AS ACTIVE INGREDIENT - The present invention relates to a composition for preventing or treating renal fibrosis comprising dimethylfumarate (DMF) as an active ingredient. The DMF according to the present invention has an excellent effect of reducing renal fibrosis by activating Nrf2 to inhibit TGF-β/Smad signaling, and thus is useful for preventing or treating renal fibrosis. | 2016-03-10 |
20160067207 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS - Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction. | 2016-03-10 |
20160067208 | ADHESION PREVENTING AGENT - The present invention relates to an adhesion preventing agent comprising an amphipathic compound having the following general formula (I): | 2016-03-10 |
20160067209 | PTEROCARPAN COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE OR COMPLICATION THEREOF, OR FOR ANTIOXIDANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits α-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity. | 2016-03-10 |
20160067210 | USE OF RHODAMINE DYES TO REDUCE ALVEOLAR SURFACE TENSION - Rhodamine dye is delivered to regions of a lung having heterogeneous alveolar flooding by alveolar liquid, thereby lowering the surface tension of the alveolar liquid so as to lessen ventilation injury directly and, by promoting equitable redistribution of the alveolar liquid among the alveoli of the lung, indirectly. The rhodamine dye is delivered with an albumin and/or an exogenous surfactant. Exemplary rhodamine dyes include sulforhodamine B and rhodamine WT. | 2016-03-10 |
20160067211 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition for the prophylaxis and/or treatment of a melanoma and a precursor thereof as well as a skin and mucosa metastasis and uses and methods associated therewith. | 2016-03-10 |
20160067212 | USE OF INSULIN SIGNALING ANTAGONISTS, OPTIONALLY IN COMBINATION OF TRANSFECTION OF NON-BETA CELLS, FOR INDUCING INSULIN PRODUCTION - The invention relates to methods of inducing insulin production in non-beta-cells or converting non-beta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and methods of predicting the susceptibility of a diabetic subject to a treatment. | 2016-03-10 |
20160067213 | Combination Treatment of Cardiovascular Disease - Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy. | 2016-03-10 |
20160067214 | METHOD OF DOSING AND USE OF SOFT ANTICHOLINERGIC ESTERS - A method of treating hyperhidrosis in a mammalian subject comprising:
| 2016-03-10 |
20160067215 | Method and Composition for Treating Heart Failure - A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril. | 2016-03-10 |
20160067216 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain compositions of a | 2016-03-10 |
20160067217 | METABOLIC SYNDROME TREATMENT - Formulations and methods of providing an orally-active anti-metabolic disease Fixed Dose Combinations (FDC) for use as personalized medicine to treat different components of the Metabolic Syndrome or Insulin resistance syndrome such as Type II diabetes, Hypertension, Hyperlipidemia and Obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of NSAIDS in general and selective Cox-2 inhibitors in particular and one or more anti-T2DM or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed. | 2016-03-10 |
20160067218 | SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS - Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). | 2016-03-10 |
20160067219 | Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2016-03-10 |
20160067220 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE - The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery. | 2016-03-10 |
20160067221 | USE OF ERGOTHIONEINE FOR INDUCING ACTIVITY OF NRF2 IN CELL - A method for inducing an activity of an Nrf2 in a cell is disclosed. The method includes administering to the cell a therapeutically effective amount of an ergothioneine that induces an expression of the Nrf2, wherein the cell is a normal cell or a damaged cell resulting from an exposure to an ultraviolet radiation (UVR). | 2016-03-10 |
20160067222 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2016-03-10 |
20160067223 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2016-03-10 |
20160067224 | THERAPEUTIC COMPOUNDS - Compounds of formula I: | 2016-03-10 |
20160067225 | AROMATASE INHIBITOR-RELEASING INTRAVAGINAL DEVICE - Described herein is an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Three compounds with estradiol inhibitory capability (letrozole, anastrozole and fenbendazole) were tested in vitro using bovine granulosa cell culture. Letrozole was found to be the most efficient and potent inhibitor. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. Samples were collected over a 24 h period. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. In an in vivo study in cattle, 3 different intravaginal devices containing 3 g of letrozole were tested: Wax (with 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine, DOPE) +gel coat (n=2), Wax+gel coat (n=4) and Wax (n=4). Blood samples were collected serially from time 0 to 120 h, and daily thereafter to measure circulating concentrations of letrozole by LC/MS/MS. The addition of a letrozole-containing gel coating improved initial absorption and hastened the increase on plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged delivery from the intravaginal device. | 2016-03-10 |
20160067226 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE - The present invention is directed to methods of inhibiting LTA | 2016-03-10 |
20160067227 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical combination comprising the compound of formula I | 2016-03-10 |
20160067228 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 2016-03-10 |
20160067229 | BIOMARKERS FOR RESPONSE TO RAPAMYCIN ANALOGS - The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR in therapeutic responsiveness to rapamycin analogs. Accordingly, in non-limiting embodiments, the present invention provides for assay methods and kits for determining the presence of loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR, and methods of using such determinations in selecting a therapeutic regimen for a cancer patient and in methods of treating cancer patients. In particular non-limiting embodiments, a plurality of tumor sites are evaluated and the composite effect of the genetic background on mTOR function is assessed. | 2016-03-10 |
20160067230 | METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE - Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis. | 2016-03-10 |
20160067231 | NEW DRUG FOR THE TREATMENT AND/OR PREVENTION OF DEPRESSIVE DISORDERS - A compound having the following formula (I): | 2016-03-10 |
20160067232 | METHODS FOR TREATING A STROKE-RELATED SENSORIMOTOR IMPAIRMENT USING AMINOPYRIDINES - Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment. | 2016-03-10 |
20160067233 | METHODS AND COMPOSITIONS FOR DECREASING SALIVA PRODUCTION - The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea. | 2016-03-10 |
20160067234 | PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX - Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABA | 2016-03-10 |
20160067235 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities - The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant. | 2016-03-10 |
20160067236 | MEDICAL TREATMENTS BASED ON ANAMORELIN - Methods of treating cancer related conditions using anamorelin are described. | 2016-03-10 |
20160067237 | Sensory Stimulation for Cessation of Eating - Methods and compositions are provided for modifying the eating behavior of an individual. The compositions provide an oral stimulatory effect such as tingling, cooling, and/or warming. Consumption of the compositions after eating a desired amount of food may habituate the individual to ending a meal and serve to cue cessation of eating, assisting the individual with ending a meal at a time point before a signal of satiety has reached the brain. Consumption of the composition in lieu of snacking between meals may assist the individual with avoiding consumption of snacks. | 2016-03-10 |
20160067238 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia. | 2016-03-10 |
20160067239 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 2016-03-10 |
20160067240 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE - The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g., radiation therapy and/or other chemotherapeutic agents that are administered to a subject having a tumor, cancer or neoplasia). | 2016-03-10 |
20160067241 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS - The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof. | 2016-03-10 |
20160067242 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent. | 2016-03-10 |
20160067243 | KETOCONAZOLE ENANTIOMER IN HUMANS - Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control. | 2016-03-10 |
20160067244 | Treatment for Neurological and Mental Disorders - Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. | 2016-03-10 |
20160067245 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders - The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) | 2016-03-10 |
20160067246 | USE OF PHOSPHODIESTERASE 5A INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY - Described herein are methods of treating muscular dystrophy, including Becker's muscular dystrophy and Duchenne muscular dystrophy. The methods comprise administering a phosodiesterase 5A (PDE5A) inhibitor, such as tadalafil, to a subject in need thereof. Administering the PDE5A inhibitor has beneficial effects such as restoring functional sympatholysis, alleviating ischemic insult to dystrophin-deficient muscle membranes, reducing use-dependent muscle injury, and thus can slow muscular dystrophy disease progression. | 2016-03-10 |
20160067247 | NOVEL USE - The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). | 2016-03-10 |
20160067248 | COMBINATIONS - The present invention relates to a method of treating ovarian cancer in a female human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a ovarian cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 2-[(5-chloro-2-[[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino]-4-pyridinyl)amino]-N-methoxybenzamide, or a pharmaceutically acceptable salt thereof, and optionally 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}, to a human in need thereof. | 2016-03-10 |
20160067249 | 3-Aryl-2-((Arylamino)Methyl)Quinazolin-4-(3H)-Ones - The invention relates to novel quinazolinone compounds and their use as inhibitors of PI3 kinases, for example, PI3Kδ, for treating and/or preventing diseases, disorder, and conditions associated with modulating PI3 kinase activity. Novel 3 -aryl-2-((arylamino)methyl)quinazolin-4(3H)-one derivatives and pharmaceutically acceptable salts or solvates thereof and their use for the treatment or prevention of diseases, disorders, and conditions associated with the activity of one or more PI3 kinase, such as PI3Kδ, are disclosed. | 2016-03-10 |
20160067250 | Methods of Reducing Kinase Inhibitor Resistance - Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described. | 2016-03-10 |
20160067251 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES - This invention relates to pyrrolopyrimidine derivatives of formula (I): where R | 2016-03-10 |
20160067252 | TRANSDERMAL DELIVERY OF SILDENAFIL AND OTHER PHOSPHODIESTERASE TYPE 5 INHIBITORS - The present invention generally relates to the transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors. While transdermal transport of sildenafil in creams and other topical formulations have been previously described, propylene glycol has not previously been recognized as a transdermal enhancer. However, in some aspects of the present invention, certain concentrations of propylene glycol can have a surprising effect on the transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors, e.g., doubling the amount of transdermal delivery in some cases. | 2016-03-10 |
20160067253 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS - The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases. | 2016-03-10 |
20160067254 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2016-03-10 |
20160067255 | METHODS OF TREATING OR PREVENTING HIV IN PATIENTS USING A COMBINATION OF TENOFOVIR ALAFENAMIDE AND DOLUTEGRAVIR - The disclosure describes methods for treating or preventing HIV in a patient using a combination of tenofovir alafenamide and dolutegravir, and to compositions containing such compounds. | 2016-03-10 |
20160067256 | Inhibitors of Hemeprotein-Catalyzed Lipid Peroxidation - Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage. | 2016-03-10 |
20160067257 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY - The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain; or FP-pocket, PT-pocket or Th-pocket of telomerase and testing the compound for its ability to modulate the activity of telomerase. Compounds selected for interacting with the T-pocket or Fingers-Palm pocket of telomerase are also provided. | 2016-03-10 |
20160067258 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors - There is provided a compound of formula I: | 2016-03-10 |
20160067259 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS - Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV. | 2016-03-10 |
20160067260 | Compositions and Methods for Treating Proliferation Disorders - The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine). | 2016-03-10 |
20160067261 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION - The present invention relates to novel combinations of active ingredients for use in the prevention and/or treatment of tumors. The tumors treated by the composition according to the invention overexpress SEC62 gene and overproduce Sec62 protein. The combination of active ingredients comprises at least a SERCA inhibitor and at least a Calmodulin antagonist. | 2016-03-10 |
20160067262 | NEW POLYMORPHISMS IN ABCB1 ASSOCIATED WITH A LACK OF CLINICAL RESPONSE TO MEDICAMENTS - The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene. | 2016-03-10 |
20160067263 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT - Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use. | 2016-03-10 |
20160067264 | MEDICAMENT AND METHOD OF DIAGNOSIS - Disclosed is a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonise the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma. | 2016-03-10 |
20160067265 | Abiraterone Acetate Formulation - Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequesting agent as well as methods for producing and using such compositions are described. | 2016-03-10 |
20160067266 | STABILIZED COMPOSITION FOR TREATING PSORIASIS - A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C | 2016-03-10 |
20160067267 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT - The present invention provides for novel treatments of obesity and overweight and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (ITPP) in these disease states. | 2016-03-10 |
20160067268 | PHOSPHONATE COMPOUNDS - The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like. | 2016-03-10 |
20160067269 | Miltefosin Or Perifosin For Use In The Treatment of IBD - Miltefosin or perifosin for use in the treatment or prevention of inflammatory bowel disease (IBD). | 2016-03-10 |
20160067270 | USE OF GINSENOSIDE F2 FOR PROPHYLAXIS AND TREATMENT OF LIVER DISEASE - Provided are use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases. | 2016-03-10 |
20160067271 | Methods And Compositions For Preventing Or Treating Obesity - The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists. The A2AR pathway agonists may be administered in conjunction with a therapeutic agent having a side effect of weight gain, in order to prevent or limit that weight gain. In some instances, the A2AR pathway agonist is administered as a sleeping pill, and in other instances the A2AR pathway agonist is administered in a non-drowsy formulation. | 2016-03-10 |
20160067272 | METHODS FOR TREATING IMMUNE DISEASES - Provided herein are methods for treating or preventing an immune disease in a subject by administering a composition comprising a therapeutically effective amount of NAD+. Also provided herein are methods and assays for diagnosing an immune disease in a subject by measuring the level of NAD+ in a biological sample obtained from the subject. | 2016-03-10 |
20160067273 | Compositions and methods for preparation of synthetic alpha-gal nanoparticles and for their clinical use - The present invention is related to the field of healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes from synthetic origin for induction of recruitment and activation of macrophages within or surrounding injured tissue of treated patients. These macrophages further recruit stem cells into the injured tissues. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. This invention further teaches methods and compositions comprising molecules and nanoparticles with linked α-gal epitopes of synthetic origin for inducing recruitment and activation of macrophages into biomaterial implants for improving the conversion of such implants into functional tissues and organs within treated patients. | 2016-03-10 |
20160067274 | PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID FOR USE IN THE TREATMENT OF BLACK DISC DISEASE - The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as “black disc disease”. These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus. | 2016-03-10 |
20160067275 | CO-CROSSLINKED PHOSPHATED NATIVE AND/OR FUNCTIONALIZED POLYSACCHARIDE-BASED HYDOGEL - Phosphorylated hydrogels obtained by co-cross-linking hyaluronic acid with dextran, a process for preparing same, and a use of the hydrogel for the encapsulation and extended release of active principles as well as cells for use in regenerative human and veterinary medicine. | 2016-03-10 |
20160067276 | HOLLOW PARTICLES ENCAPSULATING A BIOLOGICAL GAS AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 2016-03-10 |
20160067277 | USE OF XENON FOR LIMITING TUMOR CELL MIGRATION - The invention relates to a gaseous composition containing xenon as active ingredient for use in preventing or limiting tumour cell migration and/or limiting or preventing metastasis formation in an individual suffering from cancer. The prevention or limitation of tumour cell migration is obtained through the action of the xenon on free cancer cells. The xenon acts on the free cancer cells carried by the blood. The effective volume proportion of xenon is between 5% and 79%, it is preferably at least 50%. The gaseous composition also contains a volume proportion of oxygen (O | 2016-03-10 |
20160067278 | DIALYSIS FORMULATION - The invention relates to a dialysis formulation, optionally a citrate containing dialysis formulation, comprising selenium (Se), optionally in combination with further trace elements selected from rubidium (Rb), cobalt (Co), molybdenum (Mo), and zinc (Zn). The dialysis formulation is intended to be used in dialysis treatment. | 2016-03-10 |
20160067279 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 2016-03-10 |
20160067280 | INTRADIALYTIC ADMINISTRATION OF SODIUM THIOSULFATE - The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the bool of toxic and metabolic waste in the patients undergoing hemodialysis, peritoneal dialysis, or gastro-intestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain therapeutic amounts of sodium thiosulfate, which when fully reconstituted for use as a single solution, deliver 20-130 mg/dl of dialysate. | 2016-03-10 |
20160067281 | CHLORINE DIOXIDE GEL AND MANUFACTURING METHOD THEREOF - A method for manufacturing chlorine dioxide gel includes the following steps: a step of dissolving peg-copolymer bis-decyltetradeceth in hot water to form an aqueous solution of peg-copolymer bis-decyltetradeceth; a step of heating the aqueous solution of peg-copolymer bis-decyltetradeceth obtained in the above step to form a gel like colloid; a step of dissolving pure chlorine dioxide gas in water to form an aqueous solution of chlorine dioxide; and a step of uniformly mixing the aqueous solution of chlorine dioxide and the colloid of peg-copolymer bis-decyltetradeceth to form a chlorine dioxide gel, whereby with the above steps, a method for manufacturing chlorine dioxide gel that stably preserves chlorine dioxide gas in a gel is provided. | 2016-03-10 |
20160067282 | Glycosaminoglycan Compositions in Combination with Stem Cells - A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided. | 2016-03-10 |
20160067283 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR - The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions. | 2016-03-10 |
20160067284 | METHOD FOR PRODUCING SHEET-SHAPED CELL CULTURE - A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture. A sheet-shaped cell culture which is produced by the production method and which has a high activity and a method for treating a disease associated with an abnormality of a tissue with the sheet-shaped cell culture. | 2016-03-10 |
20160067285 | LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY - The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof. | 2016-03-10 |
20160067286 | Formulation for Accelerating Wound Healing, Preparation Method and Administering Method of The Same - Disclosed is a formulation for accelerating wound healing, preparation method and administering method of the same. A formulation for accelerating wound healing comprises cell culture medium which is obtained by culturing transfected endothelial progenitor cells which are acquired by transfecting microRNA let-7g into endothelial progenitor cells. And the preparation method of formulation for accelerating wound healing comprises the isolating step, the transfecting step and the culturing step. A method for accelerating wound healing is implemented by administering a therapeutically effective amount of the formulation to an organism's wound. | 2016-03-10 |
20160067287 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS WITH OPTIONAL SEALANT AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components and optionally a sealant, and pharmaceutical compositions thereof. Also described are systems, apparatuses, and methods for applying the combination of micronized placental components and adhesives optionally a sealant (e.g., adhesive or gelation agent) for wound care and other medical applications. | 2016-03-10 |
20160067288 | Honey-Based Gel Composition - A honey based composition is described. The composition includes a mixture of honey, a short chain fatty alcohol and a fatty ester or wax. The composition has applications for use in wound dressings and in one embodiment may be a gel. The composition has a higher than expected storage stability, remaining stable for many weeks when held at elevated temperatures and retains all of the other desirable characteristics including anti-microbial activity. | 2016-03-10 |
20160067289 | PROBIOTIC STRAINS FOR USE IN TREATMENT OR PREVENTION OF OSTEOPOROSIS - The present invention relates to at least one probiotic strain chosen from | 2016-03-10 |
20160067290 | ENTEROCOCCUS FAECALIS BACTERIOPHAGE AND USES THEREOF - Bacteriophages are provided that infect strains of | 2016-03-10 |
20160067291 | ORAL FORMULATIONS FOR COUNTERACTING EFFECTS OF AGING - An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and | 2016-03-10 |
20160067292 | BIOACTIVE APOLAR EXTRACT CONTAINING PLANT GENETIC MATERIAL FOR TREATMENT OF MAMMALIAN DISEASES - Bioactive apolar extract of plant material containing plant genetic material to treat mammalian diseases and disorders. | 2016-03-10 |
20160067293 | EURYCOMA LONGIFOLIA EXTRACT AND ITS USE IN ENHANCING AND/OR STIMULATING IMMUNE SYSTEM - The present invention discloses the use of a composition comprising an effective amount of an extract of | 2016-03-10 |
20160067294 | COMPOSITION COMPRISING SUAEDA JAPONICA FOR PREVENTING OR ALLEVIATING DIABETES - The present invention relates to a food composition comprising | 2016-03-10 |
20160067295 | WALNUT EXTRACTS FOR NUTRACEUTICAL APPLICATIONS - The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined. | 2016-03-10 |
20160067296 | Compositions and Methods for Joint Health - The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like. | 2016-03-10 |
20160067297 | EYE-REFRESHING AGENT TO ELIMINATE AND ALLEVIATE EYE FATIGUE AND DISCOMFORT - An eye-refreshing agent, the raw materials of which include mung bean germs, eucalyptus leaves, mint leaves, clove leaves, camphor leaves and borneol. The plant cells thereof are respectively subjected to crushing, low-temperature freezing and centrifugation and sound membrane separation to prepare a water-soluble preparation. The preparation can prevent and alleviate visual fatigue and accelerate metabolism of the eye skin cells, and also has the effect of alleviating and improving eye bags and eye pseudo-wrinkles caused by eye fatigue. | 2016-03-10 |
20160067298 | MUSCADINE GRAPE SKIN EXTRACT AS TREATMENT FOR BONE METASTATIC CANCER - Muscadine Grape Skin Extract (MSKE) derived from muscadine grape ( | 2016-03-10 |
20160067299 | USE OF DIETARY FIBRE SUPPLEMENT IN A FOOD FORMULATION - Use of dietary fibre material extracted from sugarcane in the manufacture of a food product that is formulated to ameliorate the effects of intestinal tract disorders such as Coeliac's disease and Irritable Bowel Syndrome (IBS). | 2016-03-10 |
20160067300 | SUSTAINED RELEASE FORMULATIONS OF CURCUMINOIDS AND METHOD OF PREPARATION THEREOF - A sustained release curcuminoid composition having a bioavailable curcumin composition and a release rate controlling excipient. The bioavailable composition of curcumin includes a curcuminoid mixture and an added essential oil of turmeric. The curcuminoid mixture includes curcumin, demethoxycurcumin and bisdemethoxycurcumin. The added essential oil of turmeric includes about 40% to about 50% of ar-turmerone. Methods of preparing sustained release compositions having a bioavailable curcumin composition and a release rate controlling excipient. | 2016-03-10 |
20160067301 | ANTAGONISM OF ABCG4, LYN KINASE, AND C-CBL E3 LIGASE TO INCREASE PLATELET COUNT AS THERAPY FOR THROMBOCYTOPENIA - The present invention provides a method of treating a subject to increase the subject's platelet count which comprises administering to the subject an amount of one or more of an antagonist or inhibitor of ABCG4, Lyn kinase or c-CBL effective to antagonize or inhibit such ABCG4, Lyn kinase or c-CBL so as to thereby increase the subject's platelet count. | 2016-03-10 |